BERNARD KADOSH

Allopathic & Osteopathic Physicians|Internal Medicine|Advanced Heart Failure and Transplant Cardiology NEW YORK, NY NPI 1861836645

General Payments — all program years on this page

$5,282.71

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 127
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $537.04 across 16 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $393.6114
Travel and Lodging $143.432

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Abbott Laboratories $158.193
ABIOMED $90.601
NOVARTIS PHARMACEUTICALS CORPORATION $76.044
PFIZER INC. $49.542
Merck Sharp & Dohme Corporation $45.222
Ancora Heart, Inc. $39.271
One Lambda, Inc. $33.641
Acerta Pharma LLC $22.561
Amgen Inc. $21.981

By program year

Program yearAmountRecords
2018 $895.7922
2019 $1,729.4418
2020 $44.812
2021 $363.0411
2022 $681.5015
2023 $1,031.0943
2024 $537.0416

Records — PY2024 (16)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1069830867 Ancora Heart, Inc. $39.27 11/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1069832250 One Lambda, Inc. $33.64 05/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087154832 Novartis Pharmaceuticals Corporation $18.42 05/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087154836 Novartis Pharmaceuticals Corporation $14.50 07/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087154838 Novartis Pharmaceuticals Corporation $13.22 07/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1087154858 Novartis Pharmaceuticals Corporation $29.90 11/22/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105560030 AstraZeneca Pharmaceuticals LP $22.56 10/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111612477 Amgen Inc. $21.98 09/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125311872 Abbott Laboratories $14.76 10/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125439119 Abbott Laboratories $134.41 10/26/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1125439121 Abbott Laboratories $9.02 10/26/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1131123180 PFIZER INC. $27.77 11/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131424376 PFIZER INC. $21.77 04/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141863109 Merck Sharp & Dohme LLC $20.78 10/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1141928261 Merck Sharp & Dohme LLC $24.44 12/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142224026 ABIOMED $90.60 10/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.